Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy

Klin Wochenschr. 1986 Apr 15;64(8):362-5. doi: 10.1007/BF01728184.


Twenty nonseminomatous testicular cancer patients not pretreated with emetogenic chemotherapy were included in a crossover study of antiemetic therapy. Patients were randomly assigned to receive either nabilone (2 X 2 mg/day) or alizapride (3 X 150 mg/day) prior to beginning low-dose cisplatin chemotherapy. Patients on nabilone had significantly fewer episodes of emesis than those on alizapride (medians, 1.1 vs 2.9; p less than 0.01). Nabilone was superior to alizapride in giving complete relief from nausea (medians, 65% vs 30%; p less than 0.01), and was more effective in shortening the duration of nausea (medians, 1.3 h vs 5.1 h; p less than 0.01); however, it caused more adverse effects. It is concluded that nabilone has greater antiemetic activity than alizapride in young patients receiving low-dose cisplatin chemotherapy. Nabilone dosage should be reduced to decrease the incidence and degree of adverse reactions while leaving the definite antiemetic activity unchanged.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Antiemetics / therapeutic use*
  • Cisplatin / adverse effects*
  • Cisplatin / therapeutic use
  • Dose-Response Relationship, Drug
  • Dronabinol / analogs & derivatives*
  • Dronabinol / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Pyrrolidines / therapeutic use*
  • Testicular Neoplasms / drug therapy*
  • Vomiting / chemically induced*
  • Vomiting / drug therapy


  • Antiemetics
  • Pyrrolidines
  • nabilone
  • Dronabinol
  • alizapride
  • Cisplatin